- Alnylam's announcement on ILLUMINATE-B was light on details, but management talked about "clinically significant" efficacy in young pediatric patients with PH1 and a clean safety profile.
- Management formalized its agreement with Blackstone concerning R&D funding for vitusiran and ALN-AGT.
- Pfizer believes ATTR-CM remains significantly under-diagnosed and is launching two studies in LVH and HFpEF to explore how prevalent underlying ATTR-CM may be in this conditions.
- Alnylam shares continue to look undervalued below the $150's.
For further details see:
Alnylam Reports Another Positive Study Outcome, Securing More Of Its Future Revenue Growth